By Fineline Cube 
China’s Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has received approval from the National Medical Products Administration (NMPA) to carry out a Phase II clinical study for its novel EGFR×HER3 bispecific antibody-drug conjugate (ADC) iza-bren (BL-B01D1). The study will evaluate the efficacy and safety of iza-bren combined with lenvatinib ± pembrolizumab in advanced renal cell carcinoma (RCC).
Iza-bren: A First-in-Class Bispecific ADC
Iza-bren represents a significant innovation in the field of oncology as a first-in-class EGFR×HER3 bispecific ADC. This novel therapeutic approach is designed to target cancer cells with precision, enhancing treatment outcomes for patients with advanced RCC.
Global Clinical Development
The drug is currently the subject of over 40 clinical trials across China and the U.S. for multiple tumor types. The most advanced program has reached Phase III, underscoring the potential of iza-bren to address significant unmet medical needs in oncology.-Fineline Info & Tech